France Pirenne

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8879154/publications.pdf

Version: 2024-02-01

41	1,038	686830 13	433756 31
papers	citations	h-index	g-index

46	46	46	961
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Advances, 2020, 4, 327-355.	2.5	241
2	How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions. Blood, 2018, 131, 2773-2781.	0.6	109
3	Delayed hemolytic transfusion reaction in adult sickleâ€cell disease: presentations, outcomes, and treatments of 99 referral center episodes. American Journal of Hematology, 2016, 91, 989-994.	2.0	103
4	Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease. American Journal of Hematology, 2017, 92, 1340-1348.	2.0	85
5	Control of Humoral Response in Renal Transplantation by Belatacept Depends on a Direct Effect on B Cells and Impaired T Follicular Helper-B Cell Crosstalk. Journal of the American Society of Nephrology: JASN, 2018, 29, 1049-1062.	3.0	78
6	Complement activation in sickle cell disease: Dependence on cell density, hemolysis and modulation by hydroxyurea therapy. American Journal of Hematology, 2020, 95, 456-464.	2.0	46
7	Hemolytic transfusion reactions in sickle cell disease: underappreciated and potentially fatal. Haematologica, 2020, 105, 539-544.	1.7	44
8	Nonclassical FCGR2C haplotype is associated with protection from red blood cell alloimmunization in sickle cell disease. Blood, 2017, 130, 2121-2130.	0.6	37
9	A diagnostic nomogram for delayed hemolytic transfusion reaction in sickle cell disease. American Journal of Hematology, 2016, 91, 1181-1184.	2.0	35
10	Dense red blood cell and oxygen desaturation in sickleâ€cell disease. American Journal of Hematology, 2016, 91, 1008-1013.	2.0	25
11	Individual red blood cell fetal hemoglobin quantification allows to determine protective thresholds in sickle cell disease. American Journal of Hematology, 2020, 95, 1235-1245.	2.0	18
12	Genotyping in Sickle Cell Disease Patients: The French Strategy. Transfusion Medicine and Hemotherapy, 2018, 45, 264-270.	0.7	16
13	The role of Complement in Post-Transfusion Hemolysis and Hyperhemolysis Reaction. Transfusion Medicine Reviews, 2019, 33, 225-230.	0.9	16
14	Identification of genetic biomarkers for alloimmunization in sickle cell disease. British Journal of Haematology, 2019, 186, 887-899.	1.2	14
15	High immunogenicity of red blood cell antigens restricted to the population of African descent in a cohort of sickle cell disease patients. Transfusion, 2018, 58, 1527-1535.	0.8	13
16	Evidence of benefits from using fresh and cryopreserved blood to transfuse patients with acute sickle cell disease. Transfusion, 2016, 56, 1730-1738.	0.8	12
17	Insights into antiâ€D formation in carriers of RhD variants through studies of 3D intraprotein interactions. Transfusion, 2021, 61, 1286-1301.	0.8	12
18	How to avoid the problem of erythrocyte alloimmunization in sickle cell disease. Hematology American Society of Hematology Education Program, 2021, 2021, 689-695.	0.9	12

#	Article	IF	Citations
19	Antiâ€HI can cause a severe delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease patients. Transfusion, 2016, 56, 1828-1833.	0.8	11
20	Design of the DREPAGREFFE trial: A prospective controlled multicenter study evaluating the benefit of genoidentical hematopoietic stem cell transplantation over chronic transfusion in sickle cell anemia children detected to be at risk of stroke by transcranial Doppler (NCT 01340404). Contemporary Clinical Trials, 2017, 62, 91-104.	0.8	11
21	Donor-targeted serotherapy as a rescue therapy for steroid-resistant acute GVHD after HLA-mismatched kidney transplantation. American Journal of Transplantation, 2020, 20, 2243-2253.	2.6	11
22	The cause and pathogenesis of hemolytic transfusion reactions in sickle-cell disease. Current Opinion in Hematology, 2019, 26, 488-494.	1.2	10
23	Blood microparticles are a component of immune modulation in red blood cell transfusion. European Journal of Immunology, 2020, 50, 1237-1240.	1.6	10
24	Alloimmunization risk associated with amino acid 223 substitution in the RhD protein: analysis in the light of molecular modeling. Transfusion, 2018, 58, 2683-2692.	0.8	9
25	Anti-CD20 Antibody Prevents Red Blood Cell Alloimmunization in a Mouse Model. Journal of Immunology, 2017, 199, 3771-3780.	0.4	8
26	A Review of the Literature Organized Into a New Database: RHeference. Transfusion Medicine Reviews, 2021, 35, 70-77.	0.9	8
27	Whole-blood phenotyping to assess alloimmunization status in transfused sickle cell disease patients. Blood Advances, 2021, 5, 1278-1282.	2.5	7
28	Red blood cells for transfusion in patients with sepsis: respective roles of unit age and exposure to recipient plasma. Transfusion, 2017, 57, 1898-1904.	0.8	5
29	<scp>HLA</scp> molecule expression on the surface of cells and microparticles in platelet concentrates. Transfusion, 2021, 61, 1023-1028.	0.8	5
30	Ex Vivo Activation of Red Blood Cell Senescence by Plasma from Sickle-Cell Disease Patients: Correlation between Markers and Adhesion Consequences during Acute Disease Events. Biomolecules, 2021, 11, 963.	1.8	5
31	Wholeâ€blood CCR7 expression and chemoattraction in red blood cell alloimmunization. British Journal of Haematology, 2021, 194, 477-481.	1.2	4
32	TIGIT-positive circulating follicular helper T cells and sickle cell alloimmunization. Haematologica, 2015, 100, 1371-1373.	1.7	3
33	Clinical severity in adult warm autoimmune hemolytic anemia and its relationship to antibody specificity. Haematologica, 2018, 103, e35-e38.	1.7	3
34	Predisposing factors for antiâ€D immune response in D^{â^'} patients with chronic liver disease transfused with D⁺ platelet concentrates. Transfusion, 2019, 59, 1353-1358.	0.8	3
35	Dominant immune response to HLAâ€B57/B58 molecules after platelet transfusion. Transfusion, 2020, 60, 2807-2814.	0.8	3
36	New molecular basis associated with <scp>CD36</scp>â€negative phenotype in the <scp>subâ€Saharan African</scp> population. Transfusion, 2020, 60, 2482-2488.	0.8	3

#	Article	IF	Citations
37	Cytokine changes in sickle-cell disease patients as markers predictive of the onset of delayed hemolytic transfusion reactions. Cytokine, 2020, 136, 155259.	1.4	2
38	Heme control to major B (cell): are you listening?. Blood, 2021, 137, 153-154.	0.6	1
39	<scp>RHCE</scp>*01 <scp>48G</scp>>C, 366del allele with silenced <scp>RHCE</scp>*ce expression. Transfusion, 2021, 61, E53-E54.	0.8	0
40	First report of a null allele on a GYPB*s background: GYPB*s(37â€‰+â€‰4_8delAGTGA). Transfusion, 2022, 62, .	0.8	0
41	Detection and follow-up of a soluble alpha-haemoglobin pool in the red cells of stored blood units. Blood Transfusion, 2021, , .	0.3	0